Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis.

Autor: Marano M; DEA Intensive Care Unit, IRCCS 'Bambino Gesù' Children Hospital, Piazza S. Onofrio 4, Rome, 00165, Italy. marco.marano@opbg.net., Bottaro G; Department of Pediatrics 'Tor Vergata University', Rome, Italy., Goffredo B; Laboratory of Analytical Biochemistry, IRCCS 'Bambino Gesù' Children Hospital, Rome, Italy., Stoppa F; DEA Intensive Care Unit, IRCCS 'Bambino Gesù' Children Hospital, Piazza S. Onofrio 4, Rome, 00165, Italy., Pisani M; DEA, IRCCS 'Bambino Gesù' Children Hospital, Rome, Italy., Marinaro AM; Department of Pediatrics, Section of Pediatrics Haematology and Oncology, University of Sassari, Sassari, Italy., Deodato F; Department of Pediatric Medicine, Division of Metabolism, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy., Dionisi-Vici C; Department of Pediatric Medicine, Division of Metabolism, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy., Clementi E; Scientific Institute IRCCS Eugenio Medea, 23842 Bosisio Parini, Lecco, Italy.; Department of Biomedical and Clinical Sciences L. Sacco, Unit of Clinical Pharmacology, CNR Institute of Neuroscience, 'Luigi Sacco' University Hospital, University of Milano, Milan, Italy., Falvella FS; Department of Biomedical and Clinical Sciences, Unit of Clinical Pharmacology, 'Luigi Sacco' University Hospital, University of Milano, Milan, Italy.
Jazyk: angličtina
Zdroj: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2016 Feb; Vol. 72 (2), pp. 247-8. Date of Electronic Publication: 2015 Sep 24.
DOI: 10.1007/s00228-015-1956-2
Databáze: MEDLINE